Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 10
Semaglutide in Pakistan: 30-Week Data
A 30-week Pakistan study linked biosynthetic semaglutide with lower HbA1c and weight, but its single-arm design limits causal conclusions.
Semaglutide weight-loss timelines explained
Semaglutide trial averages can set context, but they cannot predict how much weight one person will lose or when.
GLP-1R-Gs Molecular Dynamics Study
A 2026 simulation compared GLP-1, semaglutide, and tirzepatide at GLP-1R-Gs, finding structural hypotheses rather than clinical outcomes.
HIV Weight Gain and Semaglutide
HIV-associated weight gain can involve visceral fat. Here is what a small semaglutide trial found, and what it cannot answer.
Semaglutide and Asthma-COPD Overlap
A network meta-analysis linked injectable semaglutide with fewer asthma-COPD overlap events, but the respiratory outcome was rarely prespecified.
PCSK5 Heart Repair Mouse Study
A patient-linked and mouse study tied endothelial PCSK5 to angiogenesis, cardiac repair, and one preclinical semaglutide response.
Semaglutide and frailty: what we know
A new JAMA report raises questions about semaglutide across frailty levels. Here is what its headline can and cannot establish.
Who Fits Semaglutide Heart Criteria?
A registry study mapped cardiology patients to SELECT and SOUL criteria. It estimates potential semaglutide eligibility, not who should be treated.
Semaglutide Kidney Mechanism Trial
A randomized kidney study found negative primary MRI outcomes but secondary vascular and tissue signals that may explain semaglutide's effects.
Semaglutide MicroRNA Pilot Study
A 31-person semaglutide pilot found eight nominal microRNA changes, but none remained significant after correcting for multiple tests.
Can Anti-Doping Tests Detect Semaglutide?
A 2026 study describes a urine method for detecting markers of oral semaglutide exposure, with important limits on what it can show.
Weight Loss and Sleep Apnea: 2026 Review
A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.